Thelansis

Familial Partial Lipodystrophy (FPLD) Market Outlook Thelansis’s “Familial Partial Lipodystrophy (FPLD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Familial Partial Lipodystrophy (FPLD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the g...

Familial Partial Lipodystrophy (FPLD) Market Outlook Thelansis’s “Familial Partial Lipodystrophy (FPLD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Familial Partial Lipodystrophy (FPLD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Familial Partial Lipodystrophy (FPLD) Overview Familial Partial Lipodystrophy (FPLD) refers to a group of rare, genetically inherited disorders characterized by abnormal distribution and dysfunction of white adipose tissue, typically manifesting as selective loss of subcutaneous fat from the limbs, buttocks, and hips, while fat may accumulate in the face, neck, and visceral regions. This pheno...

 Familial Partial Lipodystrophy (FPLD) syndromes are a heterogeneous group of genetically inherited or acquired conditions characterised by dysfunctional white adipose tissue. It is characterised by selective loss of adipose tissue in the extremities and gluteal region without changing abdominal and visceral fat. In most cases, abnormal fat distribution becomes apparent at puberty. This selective deficiency of metabolically active adipose tissue is tightly linked with a wide range of metabolic complications, such as insulin resistance, lipoatrophic diabetes, dyslipidemia with severe hypertriglyceridemia, hypertension or hepatic steatosis. Moreover, female patients often develop hyperandrogenism, hirsutism, polycystic ovaries and infertility. The extent of fat loss often determines the severity of metabolic consequences. There are seven subtypes of FPLD caused by mutations in various genes (LMNA, PPARG, PLIN1, CIDEC, LIPE, AKT2 or CAV1); the condition can be inherited in either a do...